News headlines about XBiotech (NASDAQ:XBIT) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. XBiotech earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7244894019442 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of XBiotech (XBIT) traded down $0.08 during mid-day trading on Friday, reaching $4.60. The company had a trading volume of 22,798 shares, compared to its average volume of 96,214. The stock has a market cap of $174.35 and a price-to-earnings ratio of -2.83. XBiotech has a one year low of $2.77 and a one year high of $20.18.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/02/xbiotech-xbit-receives-news-impact-rating-of-0-03.html.
XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.